Introduction
Th e annual meeting of the American Society of Human Genetics is a major some would say overwhelming conference that aims to present the state of the fi eld as a whole, with presentations on nearly all aspects of human genetics. Th is year, the meeting had a record number of nearly 7,000 participants, with approximately 450 scien tifi c presentations and over 3,200 posters. In addition, more than 200 vendors presented their products, includ ing all major DNA sequencing companies, bioinformatic services for data analysis, and clinics specializing in genetic medicine. In order to navigate this scientifi c maze, the organizers developed a smartphone application to allow users to browse abstracts based on schedule, presenter, and topic, and to generate a snapshot of the current events at the conference. Intriguing buzzwords had participants running back and forth between rooms to hear speakers from parallel sessions.
Some of the most frequent terms used throughout the meeting, according to quantitative text analysis of #ASHG2012 tweets, were 'rare' and 'common' with both almost equally represented. Indeed, in the spirit of the US presidential election, which coincided with the fi rst day of the meeting, there seemed to be a common and rare variant party division. Entire sessions were devoted exclusively to either class of variant, such as 'GWAS from head to toe' and 'Cancer genetics I: rare variants' . In an attempt to fi nd a bipartisan resolution, one session was dedicated to 'Common variants, rare variants, and everything in between' , and presented the advantages of an integrated approach that examines association signals of both variant classes. Interestingly, several talks showed that such integrative studies based on whole exome sequencing can simultaneously replicate known genome wide association study (GWAS) signals and uncover a distinct set of genes that harbor rare etiological variations.
The interpretation gap
A recurrent issue throughout the meeting was the gap between data generation and data interpretation, espe cially for rare variants. Th is challenge is exacerbated by the application of sequencing in the clinic, where evaluation of pathogenic variants and incidental fi ndings may determine the course of treatment. A signifi cant number of talks described potential techniques to over come this interpretation gap. Some speakers, such as Heidi Rehm (Harvard Medical School, USA) suggested the development of specifi c databases for clinical inter pre tation. Others, including Marc Greenblatt (University of Vermont, USA), focused on the development of standards for variant interpretation. Another set of presen tations described the recent successes of commu nitybased interpretation contests, such as Boston Children's Hospital's CLARITY challenge and Berkeley's Critical Assessment of Genome Interpretation.
Th e main challenge when studying rare variants is that robust statistical inference of their eff ects in casecontrol studies requires a large amount of sequencing data. Daniel MacArthur (Massachusetts General Hospital, USA) suggested a brute force approach that includes sequencing a large number of individuals, postulating that 'in order to understand one genome, we need to sequence tens of thousands of genomes. '
Family studies: a shortcut to analyze rare variants
Other speakers suggested alternative, more effi cient approaches to rare variant interpretation. In fact, one of the prevailing themes at this year's meeting was the renewed interest in large pedigrees and isolated popu la tions to assess the eff ect of rare variants on common traits. Michael Province (Washington University, USA) presented one potential problem of the brute force approach in a session centered on family studies as a means to investigate complex traits. Citing recent studies about rapid population growth in humans, he noted that the number of extremely rare alleles in the population is much higher than thought. Even doubling the sample size does not help very much, as the new sample will simply present new rare alleles, rather than add statistical power. As an alternative, he suggested focusing on large pedi grees, where the allelic diversity is smaller: 'pedigrees make the needle [rare variants] in the haystack bigger' and thus easier to find. Further, the extensive identityby descent (IBD) between individuals helps to distinguish true rare variant calls from sequencing errors and pro vides a means to verify novel alleles in multiple related individuals.
Robert Elston (Case Western Reserve University, USA) was the most insistent about the current appeal of family studies in a special session recognizing his 80th birthday. He went so far as to say that 'somehow, for the last decade or so, we were misguided into thinking that families were not necessary, and we have seen epidemiologists having a ball with casecontrol studies and honestly believing that they are doing genetic research!' Elston did say that family studies may one day in the distant future be dispen sable, but maintained that, for now, it is crucial to study variants in the context of inheritance, rather than simply as DNA.
From interpretation bottlenecks to genetic bottlenecks
In addition to the renewed interest in family studies, several speakers highlighted the value of studying isolated populations. Jeffrey O'Connell (University of Maryland, USA) described a study of complex traits in the Amish population, in which he found a steady increase in the inbreeding coefficient in the last 200 years. He showed that, on average, a pair of individuals is as genetically similar as first cousins once removed. With such a strong genetic bottleneck, rare variants that segregate in the European population may increase by orders of magnitude in the Amish population, enabling robust statistical inference about their roles. To stress this point, he concluded his talk with a reminder that 'we study the Amish not because they are different but because they are us. ' William Scott (University of Miami, USA) and Cornelia van Duijn (Erasmus University Rotterdam, the Nether lands) presented an integrative approach for identifying pathogenic variants of complex disorders in isolated populations. Their method starts with linkage analysis to find large segments that segregate with a given pheno type, followed by whole exome sequencing to pinpoint the pathogenic variant in the linkage interval. This tech nique showed mixed results. They were able to uncover a rare pathogenic variant in a study of depression but found no coherent signal in a study of Parkinson's disease, suggesting a potential role for noncoding variants.
Other presenters tried to reconcile the advantages of both traditional casecontrol and family studies. Hua Zhou (UCLA, USA) discussed combining genomewide association mapping with pedigrees for quantitative trait locus analysis. Similarly, Richard Spritz (University of Colorado Denver, USA) presented an approach that integrates GWAS with the sequencing of siblings under a linkage peak. Elizabeth Thompson (University of Wash ing ton, USA) discussed using IBD within and between pedigrees, echoing Robert Elston's emphasis on the need for information on relatedness. She concluded that, eventually, pedigree and population studies will be equivalent, in the sense that we can use techniques for analyzing IBD to obtain the same information.
Conclusion
In the past few years, we have witnessed the emergence of largescale sequencing projects to study common diseases, such as the NHGRI's ClinSeq study, NHLBI's Exome Sequencing Project, and The Personal Genome Project. The renewed interest in large pedigrees and isolated populations for complex trait studies at this year's meeting was refreshing. Several speakers high lighted the advantages of such designs in interpreting the role of rare genetic variations. In addition to facilitating the ascertainment of multiple individuals with the same rare variant, the substantial IBD in the samples promotes imputation and increases confidence in the sequencing results. Further, these designs afford a set of comple men tary tools, including linkage analysis and heritability measurements, that can accelerate genetic investigation.
By definition, personalized medicine entails drawing conclusions based on the study of a single genome from the general population. Despite the tremendous advan tages of family and isolated population study designs, we should also remember that they do not entirely reflect the general population. For instance, the substantial IBD between participants in these studies increases the likeli hood of overestimating the effect of a variant due to epistasis, a point that was emphasized in the opening talk at ASHG 2010 by Eric Lander (Broad Institute, USA). Another potential complication is the sampling of indi viduals from narrow environmental conditions, which is more prone to confounding geneenvironment inter actions. Evidently, nothing comes free in human genetics. Each study design has its own limitations and advantages, necessitating an integrative approach to bridge the inter pretation gap and effectively handle today's population scale datasets.
Meeting tweets are available online at #ashg2012.
